55018-89-8

Upstream product

• 3686-57-5 2,4-dimethoxy-6-methylbenzoic acid 
• 13321-73-8 2-bromo-1,5-dimethoxy-3-methylbenzene 

Downstream Products

• 884502-04-9 2,4-dimethoxy-N,6-dimethylbenzamide 
• 1044871-96-6 C₂₆H₃₅NO₄Si 
• 1044872-78-7 C₂₅H₃₃NO₄Si 
• 1044870-23-6 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxy-2-methyl-isoquinoline-1(2H)-one 
• 924300-40-3 3-{4-[2-[(tert-butyl dimethylsilyl)oxy]-2-methylpropoxy]-3,5-dimethylphenyl}-6,8-dimethoxy-2H-isoquinolin-1-one 
• 56974-44-8 Calphostin D 
• 56974-44-8 isophleichrome 
• 133363-21-0 5,5'-Bis-benzyloxy-7,7'-bis-[(S)-2-(tert-butyl-diphenyl-silanyloxy)-propyl]-2,6,2',6'-tetramethoxy-4,4'-bis-methoxymethoxy-[1,1']binaphthalenyl 
• 133363-21-0 5,5'-Bis-benzyloxy-7,7'-bis-[(S)-2-(tert-butyl-diphenyl-silanyloxy)-propyl]-2,6,2',6'-tetramethoxy-4,4'-bis-methoxymethoxy-[1,1']binaphthalenyl 
• 133363-21-0 5,5'-Bis-benzyloxy-7,7'-bis-[(R)-2-(tert-butyl-diphenyl-silanyloxy)-propyl]-2,6,2',6'-tetramethoxy-4,4'-bis-methoxymethoxy-[1,1']binaphthalenyl 
• 133363-21-0 5,5'-Bis-benzyloxy-7,7'-bis-[(R)-2-(tert-butyl-diphenyl-silanyloxy)-propyl]-2,6,2',6'-tetramethoxy-4,4'-bis-methoxymethoxy-[1,1']binaphthalenyl 
• 133363-19-6 [(S)-2-(4-Benzyloxy-8-bromo-3,7-dimethoxy-5-methoxymethoxy-naphthalen-2-yl)-1-methyl-ethoxy]-tert-butyl-diphenyl-silane 
• 133363-23-2 [(R)-2-(4-Benzyloxy-8-bromo-3,7-dimethoxy-5-methoxymethoxy-naphthalen-2-yl)-1-methyl-ethoxy]-tert-butyl-diphenyl-silane 
• 120461-92-9 calphostin A 

Relevant academic research and scientific papers

NADPH OXIDASE INHIBITORS AND USES THEREOF

This disclosure relates to compounds and methods of treating or preventing a Nox related disease or condition comprising administering to a subject in need thereof a Nox inhibitor or pharmaceutical compositions comprising a Nox inhibitor disclosed herein,

Design, synthesis, and biological evaluation of inhibitors of the NADPH oxidase, Nox4

NADPH oxidases (Nox enzymes) are critical mediators of both physiologic and pathophysiologic processes. Nox enzymes catalyze NADPH-dependent generation of reactive oxygen species (ROS), including superoxide and hydrogen peroxide. Until recently, Nox4 was proposed to be involved exclusively in normal physiologic functions. Compelling evidence, however, suggests that Nox4 plays a critical role in fibrosis, as well as a host of pathologies and diseases. These considerations led to a search for novel, small molecule inhibitors of this important enzyme. Ultimately, a series of novel tertiary sulfonylureas (23–25) was designed using pharmacophore modeling, synthesized, and evaluated for inhibition of Nox4-dependent signaling.

First total synthesis of kipukasin A

In this paper, a practical approach for the total synthesis of kipukasin A is presented with 22% overall yield by using tetra-O-acetyl-β-D-ribose as starting material. An improved iodine-promoted acetonide-forming reaction was developed to access 1,2-O-is

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotei? A-I (ApoA-l), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES

The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

Modular synthesis of radicicol A and related resorcylic acid lactones, potent kinase inhibitors

(Chemical Equation Presented) Short and sweet: A concise and modular synthesis of radicicol A and related resorcylic acid lactones using fluorous isolation technology and immobilized reagents is reported (see scheme, R F = C3H6

Solution- and solid-phase synthesis of radicicol (monorden) and pochonin C

A modular synthesis for pochonin C and radicicol is reported. The two natural products were prepared in seven and eight steps, respectively, from three readily available fragments. Alternative syntheses of these compounds were achieved using a combination of polymer-bound reagents and solid phase reactions. The conformation of the two natural products was studied and compared by using 2D NMR spectroscopy.

Total synthesis of phleichrome, calphostin A, and calphostin D. Unusual stereoselective and stereospecific reactions in the synthesis of perylenequinones

This report describes the total synthesis of phleichrome, calphostin A and calphostin D - three protein kinase C inhibitory perylenequinones. The present route affords the targets in enantiomerically pure form and represents the first successful approach

Oxidative Coupling. Part 11. Approaches to the Synthesis of Bikaverin

The synthesis of orcinoylhydroquinones has been achieved by photochemical Fries rearrangement of their esters.A study of their oxidation (DDQ) shows that oxidative coupling occurs to produce a spirocyclohexenedione which can be thermally isomerised to the xanthone.The synthesis of a tetracyclic xanthone (related to bikaverin) is described.